Nolwenn Le Stang - Concepedia

Author

Nolwenn Le Stang

Also Known As

Le Stang, Nolwenn, N. Le Stang, Nolween Le Stang, Nolwenn LE STANG, Nolwenn Le Stang, Nolwenn Le-Stang, Nolwenn LeStang, Nolwenn Stang

Publications

Citations

H-Index

Concepts

All Affiliations

Centre Léon Bérard Inserm Centre de Recherche en Cancérologie de Lyon Hospices Civils de Lyon Université Claude Bernard Lyon 1

About

Nolwenn Le Stang is an author at Centre Léon Bérard specializing in medicine, pathology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	14	730
2	Health Sciences	3	3	67
3	Engineering	2	2	694
4	Immunology	2	2	112
5	Cell Biology	1	1	44

Nolwenn Le Stang

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
Deep learning-based classification of mesothelioma improves prediction of patient outcome Pierre Courtiol, Charles Maussion, Matahi Moarii, Nature Medicine Convolutional Neural NetworkEngineeringMachine LearningDeep LearningPathology	2019	534
Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer Julien Adam, Nolwenn Le Stang, Isabelle Rouquette, Annals of Oncology	2018	211
Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids Nicolas Alcala, Noémie Leblay, Alice‐Agnes Gabriel, Nature Communications	2019	205
MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma David B. Chapel, Jefree J. Schulte, Kyra B. Berg, Modern Pathology EngineeringMalignant DiseaseMedicineTheranosticsPathology	2019	160
Gonadal Function in Males After Chemotherapy for Early-Stage Hodgkin's Lymphoma Treated in Four Subsequent Trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Étude des Lymphomes de l'Adulte Marleen A. E. van der Kaaij, Natacha Heutte, Nolwenn Le Stang, Journal of Clinical Oncology	2007	98
Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study Lauren Rosen, Theodore Karrison, Vijayalakshmi Ananthanarayanan, Modern Pathology Tumoral PathologyMedicineSurgical PathologyNuclear GradePathology	2018	95
Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas Christelle Combaz-Lair, Françoise Galateau-Sallé, Anne McLeer‐Florin, Human Pathology Cancer ImmunosurveillanceImmunologyPleural DiseaseImmunotherapyMedicine	2016	90
New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center Françoise Galateau-Sallé, Nolwenn Le Stang, Andrew G. Nicholson, Journal of Thoracic Oncology	2018	90
BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas Noémie Leblay, Frédéric Leprêtre, Nolwenn Le Stang, Journal of Thoracic Oncology Protein ExpressionMalignant DiseaseMalignant Peritoneal MesotheliomasCopy Number LossPathology	2016	85
Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions Nicolas Alcala, Lise Mangiante, Nolwenn Le Stang, EBioMedicine	2019	76

Page 1